Opthea (ASX:OPT) announced the publication of data from a phase 2b trial of its sozinibercept drug candidate for wet age-related macular degeneration in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina, according to a Monday Australian bourse filing.
The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients.
The randomized, controlled trial saw sozinibercept combination therapy leading to superior visual gains compared to therapy with only ranibizumab at 24 weeks.
Analysis of the data showed that in patients with occult and minimally classic lesions, representing 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a "statistically significant" gain in best corrected visual acuity compared to ranibizumab alone.
Opthea's shares rose almost 3% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.